{{Use dmy dates|date=April 2015}}
{{Infobox company
| name             = Actelion Pharmaceuticals Ltd.
| logo             = Logo Actelion.svg
| caption          = Actelion logo
| image            = Actelion Allschwil.jpg
| type             = public company
| foundation       = 1997
| founder          = Jean-Paul Clozel, Martine Clozel, Walter Fischli, André J. Müller and Thomas Widmann
| board            = Robert Cawthorn, President of the Board [will step back in 2012]
| location_city    = Allschwil, Basel country
| location_country = Switzerland
| location         = Gewerbestrasse 16
| key_people       = Jean-Paul Clozel, Chief Executive Office <br/>Guy Braunstein, Global Clinical Development <br/> Otto Schwarz, Chief Operating Officer<br/> Nicholas Franco, Chief Business Officer<br/> André C. Muller, Chief Financial Officer|
| area_served      = Research and Development of medicines for unmet medical need
| industry         = Pharmaceuticals/Biotech
| products         = Tracleer, Ventavis, Zavesca, Veletri, Opsumit
| revenue          = 1,929 mio [[Swiss franc|CHF]]
|title=Annual Report <ref name="actelion.com">{{cite web|url=http://www.actelion.com/en/our-company/news-and-events/index.page?newsId=1489892 |deadurl=yes |archiveurl=https://web.archive.org/web/20110303032258/http://www1.actelion.com/en/our-company/news-and-events/index.page?newsId=1489892 |archivedate=3 March 2011 }}</ref>
| operating_income = 457.3 mio CHF
| net_income       = 390.6 mio CHF
| num_employees    = 2467 (January 2011)
| homepage         = {{URL|http://www.actelion.com}}
}}

'''Actelion''' is a pharmaceuticals and bio-technology company established in December 1997, headquartered in Allschwil near Basel in Switzerland.<ref name="FT 1">{{cite web|title=Financial Times|url=http://markets.ft.com/tearsheets/performance.asp?s=ch:ATLN}}</ref> Its [[Chief Executive Officer|CEO]] and co-founder is [[cardiologist]] Jean-Paul Clozel.<ref>{{cite web|title=Nature|url=http://www.nature.com/nbt/journal/v25/n2/full/nbt0207-155.html}}</ref>

Actelion specializes in [[orphan diseases]].<ref>{{cite web|title=Medicine|url = http://www.medterms.com/script/main/art.asp?articlekey=11418}}</ref> Actelion scientists were among the first to work in the field of endothelian receptor antagonists.<ref>{{cite web|title=Businessweek|url=http://investing.businessweek.com/research/stocks/snapshot/snapshot.asp?ticker=ATLN:VX}}</ref> The company name might be a reminder for its first product, an endothelian receptor antagonist and the verb "action", "act upon". Actelion was initially financed with [[venture capital]] provided through a syndicate including Atlas Venture, [[Sofinnova]] and [[HealthCap]].

Actelion has 29 operative affiliates around the world, including the United States, Canada, Brazil, Australia, Japan, Switzerland and a number of EU countries.
The Swiss affiliate is located in Baden, the German affiliate in [[Freiburg]], the Austrian one in [[Vienna]], the French one in [[Paris]] and the UK affiliate is located in [[London]]<ref>{{cite web|title=Actelion affiliates|url=http://www.pah-info.com/Affiliates}}</ref>

In 2006, the company established the Actelion Endothelin Research Award programme which supports selected clinical research projects.

In January 2017, [[Johnson & Johnson]] announced that it would purchase the company for $30 billion.<ref name=wsj-rockoff>{{Citation
| last1       =Roland 
| first1      = Denise 
| last2       = D. Rockoff
| first2      =Jonathan
| year       =January 26, 2017
| title      =Johnson & Johnson to Acquire Actelion in $30 Billion Deal
| publisher  = Wall Street Journal
| url        =https://www.wsj.com/articles/johnson-johnson-to-acquire-rare-disease-drug-maker-actelion-in-30-billion-deal-1485413057
| accessdate =January 27, 2017
}}</ref> Actelion's research and development unit would also be spun off after the acquisition.<ref>{{cite news|title=Johnson & Johnson to buy Actelion for $30 billion, spin off R&D unit|url=https://www.reuters.com/article/us-actelion-johnson-johnson-idUSKBN15A0KM|accessdate=26 January 2017|work=Reuters|date=26 January 2017}}</ref>

==Medicines==
Actelion currently has 10 compounds in its pipeline – including 3 in late-stage development – and 4 medicines on the market for [[orphan disease]]s:
* ''Tracleer'' ([[bosentan]]): Tracleer was the first oral treatment approved for [[pulmonary arterial hypertension]], a rare, chronic, life-threatening disorder that severely compromises the functions of the lungs and heart. It is a dual [[endothelin receptor antagonist]], see also: [[Endothelin receptor antagonist]].<ref>{{cite web|title=European Medicines Agency|url=http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000401/human_med_001100.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d125}}</ref>
* ''Zavesca'' ([[miglustat]]): is currently the only approved oral treatment for patients with mild to moderate type 1 [[Gaucher disease]] for whom enzyme replacement therapy is unsuitable. Type 1 Gaucher disease is a rare and debilitating metabolic disorder.<ref>{{cite web|title=European Medicines Agency|url=http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000435/human_med_001171.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d125}}</ref>
* ''Ventavis'' ([[iloprost]]): Ventavis is indicated for the treatment of pulmonary arterial hypertension (WHO Group 1) in patients with [[NYHA]] Class III or IV symptoms.<ref>{{cite web|title=European Medicines Agency|url=http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000474/human_med_001133.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d125}}</ref>
* ''Veletri'' ([[epoprostenol]] for injection): is approved by the U.S. Food and Drug Administration (FDA) for the long-term intravenous treatment of [[primary pulmonary hypertension]] and [[pulmonary hypertension]] associated with the [[scleroderma]] spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.<ref>{{cite web|title=News Medical|url=http://www.news-medical.net/news/20100826/FDA-approves-brand-name-VELETRI-for-Actelions-epoprostenol-for-injection-therapy.aspx}}</ref>

=== Pipeline ===
Late-stage drugs in development by Actelion include:
* [[Cadazolid]] for c. diff-associated diarrhea
* [[Macitentan]] for pediatric PAH and portopulmonary hypertension 
* [[Ponesimod]] for multiple sclerosis<ref>https://www1.actelion.com/en/scientists/development-pipeline/index.page?</ref>

==Key figures==
By January 2011, Actelion had a total of 2,467 employees, 392 in research, 640 in development and 1017 in sales and marketing. In 2010, Actelion's sales amounted to 1,929 million CHF.<ref>{{cite web|title=Actelion company homepage|url=http://www.actelion.com/en/our-company/actelion-worldwide/index.page?}}</ref>

Actelion's shares have been listed on the SIX Swiss Exchange (ticker symbol ATLN) since 2000 [[Swiss Exchange|SWX Swiss Exchange]] [[Swiss Leader Index]]. In September 2008, Actelion shares began trading as part of the [[Swiss Market Index]].<ref name="FT 1"/><ref>{{cite web|title=Swiss Market Index|url=http://www.six-swiss-exchange.com/shares/security_info_en.html?id=CH0010532478CHF1}}</ref><ref>{{cite web|title=UBS|url=https://www.ubs.com/global/en/bcqv/quotes.html?m%28bcvProfile%29=BCQV_CH&m%28lang%29=en&m%28searchBySymbol%29=GO&m%28searchInput%29=actelion&m%28bcvProfile%29=BCQV_CH&m%28lang%29=en&m%28searchBySymbol%29=GO&m%28searchInput%29=actelion}}</ref><ref>{{cite web|title=The Pharmaletter|url=http://www.thepharmaletter.com/file/89778/switzerlands-actelion-going-public-in-one-of-europes-biggest-biotech-ipos.html}}</ref>

== Awards ==
Actelion received the "Prix Hermès de l'innovation" (Hermès Award for Innovation) in April 2011:<ref>{{cite web|title=Prix Hermès |url=http://www.rencontre-innovation.com/?page_id=7 |archive-url=https://web.archive.org/web/20101221030634/http://www.rencontre-innovation.com/?page_id=7 |dead-url=yes |archive-date=2010-12-21 }}</ref> The "European Institute for Creative Strategy and Innovation", the creator of the Prix Hermès, was founded in 2003 in France.

The "performance report for Swiss pharma websites" awarded Actelion the first Prize in the second consecutive year:.<ref>{{cite web|title=Prize for Website |url=http://www.sitemorse.ch/pub/uploads/editor/files/SiteMonitor201101Online.pdf |deadurl=yes |archiveurl=https://web.archive.org/web/20120323153119/http://www.sitemorse.ch/pub/uploads/editor/files/SiteMonitor201101Online.pdf |archivedate=23 March 2012 }}</ref>

==Notes and references==
{{Reflist|2}}

== See also ==
* [[List of pharmaceutical companies]]
* [[Pharmaceutical industry in Switzerland]]

==External links==
{{Commons category|Actelion}}
* [http://www.actelion.com Official website]
* [http://www.endothelin.org/Rainbow/ Official AERA website]{{dead link|date=October 2016 |bot=InternetArchiveBot |fix-attempted=yes }}

{{Swiss Market Index companies}}
{{Portal bar|Companies|Switzerland}}

[[Category:Pharmaceutical companies of Switzerland]]
[[Category:Pharmaceutical companies established in 1997]]
[[Category:Orphan drug companies]]
[[Category:Life sciences industry]]
[[Category:Swiss brands]]